ArticleJournal of neurology2026
External validation of KFLC index threshold for multiple sclerosis diagnosis in a French cohort.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe kappa free light chains (KFLC) index was recently incorporated into the 2024 McDonald criteria as a practical alternative to oligoclonal bands (OCB) in multiple sclerosis (MS) diagnosis. Our objectives were to compare the diagnostic performance of KFLC index and OCB, evaluate the recommended KFLC index threshold of 6.1, and assess the correlation between KFLC index and disease activity.
methodsWe conducted a retrospective study on patients referred to the Lyon MS center who underwent lumbar puncture for OCB assessment from October 2019 to November 2023. KFLC index was measured on stored CSF and serum samples. Patients were classified as MS, other inflammatory neurological disease (OIND), or non-inflammatory neurological disease controls (NINDC).
resultsWe included 262 patients (153 MS, 62 OIND, 47 NINDC). The median KFLC index was significantly higher in MS patients (42 [IQR 13.5-108.3]) compared to OIND (2.7 [1.5-7.4], p < 0.001) and NINDC (1.6 [1-6.5], p < 0.001). The optimal threshold in our cohort was 5.48, yielding sensitivity of 89.5% and specificity of 83.5%, comparable to OCB (92.8% and 80.7%). The 6.1 threshold also performed well (sensitivity 87.6%, specificity 83.5%), though it may be suboptimal in male patients. KFLC index was significantly higher in active MS and in patients with high lesion load at imaging.
conclusionOur study confirms the strong diagnostic performance of the KFLC index, suggests a correlation with disease activity and lesion load and supports the 6.1 threshold from the 2024 McDonald criteria, while highlighting the importance of maintaining OCB testing in selected cases.
Indexed as
Identifiers
42469422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.